Welcome to the International AIDS Society-USA - 11th Annual Clinical Update for Ryan White HIV/AIDS Program, August 25-27, 2008

Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”

Overview

Archive, CME credit no longer available
Release Date: September 10, 2008
Expiration Date: September 10, 2009

The 11th Annual Clinical Update for Ryan White (RW) Parts A, B, C, and D practitioners was held in conjunction with the 2008 RW HIV/AIDS Program Grantee Meeting, “New Era, New Act,” from August 25-27, 2008 at the Marriott Wardman Park Hotel in Washington, DC.

This activity consists of audio and visual recording of 17 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.

To view a particular presentation, the learner should click on the presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he or she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.

Needs and Objectives

Upon completion of this activity, learners will be able to:

Identify current issues and future trends in the use of long-term cohort data in HIV clinical research
Discuss new effective methods for outreach to HIV patient populations and retention in care
Design antiretroviral treatment regimens that consider the recent data on
- Initiating antiretroviral therapy
- Management of complicated antiretroviral failure and drug resistance
- The role of HIV resistance testing and other assays and nuances in interpretation of the results
- The status of new investigational antiretrovirals and new classes
- Drug-drug interactions among newer approved and investigational antiretrovirals
Describe the management of hepatitis B and C viral coinfections with HIV using new approved and investigational agents
Formulate new processes for quality improvement in HIV clinics emphasizing the clinician’s role in supporting and implementing changes
Discuss the incidence, diagnosis, and management of opportunistic diseases, methicillin-resistant Staphylococcus aureau (MRSA), and dermatologic manifestations
List the major issues regarding the management of specific patient populations with HIV infection, including children, adolescents, and women

CME Credit

The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The International AIDS Society–USA designates this educational activity for a maximum of 11.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.

Intended Audience for CME Credit

This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:

Have a solid, working knowledge of HIV disease management
Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years

This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.

Course Faculty

Co-Chairs

Laura W. Cheever, MD, ScM
Chief Medical Officer
Deputy Associate Administrator
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland

Michael S. Saag, MD
Volunteer Director
International AIDS Society–USA
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Division of Infectious Diseases and The William C. Gorgas Center for Geographic Medicine
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Program Planning Committee

Laura W. Cheever, MD, ScM
Chief Medical Officer
Deputy Associate Administrator
HIV/AIDS Bureau
Health Resources and Services Administration
Rockville, Maryland

Donna M. Jacobsen
Executive Director/President
International AIDS Society–USA
San Francisco, California

Carmen D. Zorrilla, MD
Professor of Obstetrics and Gynecology
University of Puerto Rico School of Medicine
Principal Investigator: CME, PR-CCHD, HVTN-PR
Maternal and Infant Studies Center (CEMI)
San Juan, Puerto Rico

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

IAS-USA Board of Directors

Constance A. Benson, MD
Dr Benson received research grants awarded to University of California, San Diego from Gilead Sciences. Dr Benson served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Merck, and Pfizer, and chaired Data and Safety Monitoring Boards for Johnson & Johnson Research, Ltd. (Australia) and Achillion. (Updated 05/06/08)

Judith S. Currier, MD
Dr Currier (3/12/07-2/15/08) received research grants to UCLA from Tibotec, Merck, GlaxoSmithKline and Theratechnologies and served as a consultant or received honoraria from Bristol-Myers Squibb, Pfizer, Merck, and Tibotec. In addition she serves on a data safety monitoring board for Koronnis and Achillion Pharmaceuticals. (Updated 02/15/08)

Carlos del Rio, MD
Dr del Rio (3/12/07–2/15/08) received research grants to Emory University from Merck, GlaxoSmithKline, Pfizer, the CDC and the NIH. He served as a consultant or received honoraria from Merck, Trinity Biotech and BMS. (Updated 02/15/08)

Joel E. Gallant, MD, MPH
Dr Gallant received research grants awarded to Johns Hopkins University School of Medicine from Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec, and honoraria from Abbott, Gilead, GlaxoSmithKline, Monogram Biosciences, and Tibotec. He served as a scientific advisor or consultant to Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Panacos, Pfizer, RAPID Pharmaceuticals, Schering Plough, Tibotec, and Vertex. He is a member of Data Safety and Monitoring Boards for Abbott, Gilead, and Koronis. (Updated 02/15/08)

Roy M. Gulick, MD, MPH
Dr Gulick received research grants to Cornell University from Merck, Panacos, Pfizer, Schering, and Tibotec. He served as an ad-hoc scientific advisor or consultant to Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Schering, Tibotec, Trimeris, and Virostatics. He also serves as Chair of a DSMB for Koronis. (Updated 08/13/08)

Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 08/15/08)

Douglas D. Richman, MD
Dr Richman served as a consultant to Anadys, Biota, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, Idinex, Koronis, Merck, Monogram, Pfizer, Roche, and Tobira. (Updated 05/09/08)

Michael S. Saag, MD
Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco. (Updated 08/13/08)

Robert T. Schooley, MD
Dr Schooley served as a consultant to Achillion, Gilead, GlaxoSmithKline, Koronis, Merck, Monogram, Pfizer, TaiMed, Tibotec, and Vertex. He had stock options for Achillion and Monogram. (Updated 05/09/08)

Paul A. Volberding, MD
Dr Volberding, during the period from 1/1/07 through 1/1/08, served on scientific advisory boards for Bristol-Myers Squibb, Gilead, Pfizer, and Schering, and was on the endpoint adjudication committee of Schering for an ongoing clinical trial. He received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 03/05/08)

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

Dr Aberg received grants and research support or honoraria from CME activities from Abbott, Bristol-Myers Squibb, Clinical Viewpoints, Gilead, GlaxoSmithKline, Merck, Pfizer, Rush, and Tibotec. She served as a scientific advisor to GlaxoSmithKline, Pfizer, and Tibotec.

Dr Barnes has no relevant financial affiliations to disclose.

Dr Bartlett received grants from Gilead. He served as a consultant to Abbott, Arpida, Bristol-Myers Squib, GlaxoSmithKline, Johnson and Johnson, Pfizer, and Tibotec.

Dr Braithwaite has no relevant financial affiliations to disclose.

Dr Carmichael was on the speakers’ bureaus of Boehringer Ingelheim, GlaxoSmithKline, Merck, and Tibotec.

Dr Cheever has no relevant financial affiliations to disclose.

Dr Clanon has no relevant financial affiliations to disclose.

Dr Gulick received research grants to Cornell University from Merck, Panacos, Pfizer, Schering, and Tibotec. He served as an ad-hoc scientific advisor or consultant to Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Pfizer, Schering, Tibotec, Trimeris, and Virostatics. He also serves as Chair of a DSMB for Koronis.

Dr Haubrich received grants and research support for University of California San Diego from Abbott, GlaxoSmithKline, Gilead, Pfizer, and Tibotec. He received fees for lecture, written enduring materials, Internet activities, and/or audio activities from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Merck, Monogram, and Roche.

Dr Kottilil has no relevant financial affiliations to disclose.

Dr Lennox received research support from Gilead, GlaxoSmithKline, Merck, Pfizer, Schering and Tibotec. He served as a consultant to or received honoraria from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Merck, Roche, and Tibotec.

Dr Martinez has no relevant financial affiliations to disclose.

Dr Maurer has no relevant financial affiliations to disclose.

Dr Mayer received grants and research support, fees for lectures, or honoraria from Boehringer Ingelheim, Gilead, Merck, Pfizer, and Tibotec.

Dr Puga received grants and research support and honoraria from Abbott, Boehringer Ingelheim, Gilead, and Tibotec. He served as a consultant to or was on the speakers’ bureaus of Abbott, Boehringer Ingelheim, and Gilead.

Dr Mugavero received grants and research support or honoraria from Bristol-Myers Squibb and Tibotec.

Dr Rawlings served as a consultant to Abbot and GlaxoSmithKline. He received fees for lectures and honoraria from or served on the speakers’ bureaus of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Pfizer, and Tibotec.

Dr Saag received grants and research support from, and has been a scientific advisor to Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Monogram Biosciences, Panacos, Pfizer, Progenics, Roche, Tibotec, and Virco.

Dr Smith served on scientific advisory boards and or speakers’ bureaus of Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer and Tibotec.

Dr Spach received honoraria from Cubist and Merck.

Dr Sulkowski received grant and research support or honoraria for CME activities from Boehringer Ingelheim, Clinical Care Options, Chronic Liver Disease Foundation, Debiopharm, Merck, Schering, Valeant, and Vertex. He also served as a scientific advisor for Amylin, Boehringer Ingelheim, Gilead, Merck, Human Genome Sciences, Roche, and Vertex.

Dr Zorrilla received grant and research support from Bavaria-Nordic, Bristol-Myers Squibb, Pfizer, Roche, and Tibotec.

IAS–USA CME Staff

Ms Jacobsen has no relevant financial affiliations to disclose (see above).

Ms Wilson has no relevant financial affiliations to disclose (Updated 08/15/08).

Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the HIV/AIDS Bureau, Health Resources and Services Administration of the US Department of Health and Human Services, the AIDS Education and Training Centers National Resource Center, and the International AIDS Society–USA.

Contact Information

If you have any questions about this Web-based CME activity, please contact the International AIDS Society–USA:

International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org